SODIUM POLYPHOSPHATE-TIN KIT
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Oct 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sodium Polyphosphate-Tin Kit is an injectable diagnostic agent approved in 1976 by GE HealthCare. The product's specific mechanism of action and indications are not publicly detailed in available data. This appears to be a specialized radiopharmaceutical or imaging diagnostic used in nuclear medicine.
LOE Approaching
This mature, aging product faces moderate competitive pressure (30%) with declining market relevance, suggesting a small, cost-focused team managing legacy revenue.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This legacy diagnostic product offers minimal career growth opportunity with zero linked job openings. Working on this product typically involves managing end-of-life compliance, manufacturing continuity, and niche customer relationships rather than innovation or expansion.
Supply Chain ManagerRegulatory Affairs Specialist
Worked on SODIUM POLYPHOSPHATE-TIN KIT at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.